


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Insulin icodec for treating type 2 diabetes [ID6175]


Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Novo Nordisk (insulin icodec) Patient/carer groups BEMDA: Black and Ethnic Minority Diabetes Association	 All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in
 Black Health Agency for Equality Diabetes Research and Wellness Foundation Diabetes UK Haemochromatosis UK InDependent Diabetes Trust Network of Sikh Organisations South Asian Health Foundation 	 Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Diabetes UK Cymru Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care
 Specialised Healthcare Alliance Healthcare professional groups Association for the Study of Obesity Association of British Clinical Diabetologists British & Irish Hypertension Society British Association for Nursing in 	 National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 Cardiovascular Care British Geriatrics Society British Heart Foundation Primary Care Diabetes Society Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Endocrinology TREND Diabetes UK Clinical Pharmacy Association 	 Comparator companies A. Menarini Farmaceutica Internazionale (canagliflozin, metformin) AstraZeneca (exenatide, dapagliflozin, metformin, saxagliptin) Aurobindo Pharma (gliclazide, metformin, sitagliptin, vildagliptin) Bioproject (glibenclamide) Boehringer Ingelheim (empagliflozin, linagliptin, metformin) Bristol laboratories (gliclazide) Brown and Burk UK (gliclazide, glimepiride, metformin, pioglitazone) Celix Pharma (metformin, sitagliptin) Colonis Pharma (metformin)



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Others Department of Health and Social Care NHS England	 Dr Reddy's Laboratories (metformin, sitagliptin) Eli Lilly (dulaglutide, insulin, tirzepatide) Flamingo Pharma (gliclazide) Genus Pharmaceuticals (metformin, sitagliptin) Glenmark Pharmaceuticals (metformin, sitagliptin) Ipca Laboratories (metformin) Krka UK (gliclazide, sitagliptin) Lupin Healthcare (gliclazide) Morningside Healthcare (metformin) MSD (ertugliflozin, metformin, sitagliptin) Mylan (gliclazide, insulin, pioglitazone, sitagliptin) Neon Healthcare (metformin, pioglitazone) Novartis (metformin, vildagliptin) Novo Nordisk (insulin, liraglutide, semaglutide) Pfizer (glipizide) Pinewood Healthcare (metformin) Rosemont Pharmaceuticals (metformin) Sandoz (metformin, pioglitazone) Sanofi (insulin, lixisenatide) Servier Laboratories (gliclazide) Sigma Pharmaceuticals (metformin) Sovereign Medical (tolbutamide) Strides Pharma (metformin) Sun Pharmaceuticals (sitagliptin) Takeda (alogliptin, metformin) Thame Laboratories (metformin, sitagliptin) Tillomed Laboratories (metformin) Wockhardt (metformin) Zentiva (gliclazide, metformin, sitagliptin)
	 Relevant research groups Cochrane Metabolic & Endocrine Disorders Group Genomics England MRC Clinical Trials Unit National Institute for Health Research

Final stakeholder list for the evaluation of insulin icodec for treating type 2 diabetes [ID6175] Issue date: July 2024



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	The Society for Research in RehabilitationWellcome Trust
	Associated Public Health groupsPublic Health WalesUK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.


The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

Final stakeholder list for the evaluation of insulin icodec for treating type 2 diabetes [ID6175] Issue date: July 2024





All non-company commentators are invited to nominate clinical or patient experts.